Jim Cornall

This week on our podcast, explore how precision neuromedicine is reshaping neurological care with Rapport Therapeutics.

Tome Biosciences recently exited stealth mode with almost a quarter of a billion dollars in funding.

Immunai is using artificial intelligence to map the immune system. The company hopes this will lead to better and faster drug discovery.

There is a clear demand for novel, neurological treatments. While it's widely known psychedelics hold enormous therapeutic potential, there are a

Explore the latest strides in schizophrenia treatment development as 2024 heralds a pivotal year, with promising collaborations and trials.

Based in Austin, Texas , biotech Colossal Biosciences is at the forefront of de-extinction, critically endangered species protection and the repopulation of critical ecosystems.

Doloromics is a precision neuropharmaceuticals company. It was set up four years ago, to use newer technologies, particularly in the omics space, to

Dive into 2024's biotech investment strategies with RTW Investments on our podcast. Discover trends shaping the landscape ahead.

Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class

German-headquartered Isarna Therapeutics is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology – transforming growth factor beta (TGF-B) signaling.